Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)

Authors

Evanthia Galanis, Mayo Clinic
Jian Campian, Washington University School of Medicine in St. Louis
et al.

Journal

Neuro-Oncology Advances

Publication Date

1-1-2022

Volume

4

Issue

1

First Page

vdac041

Document Type

Open Access Publication

DOI

10.1093/noajnl/vdac041

Rights and Permissions

Evanthia Galanis, S Keith Anderson, Erin Twohy, Nicholas A Butowski, Adilia Hormigo, David Schiff, Antonio Omuro, Kurt A Jaeckle, Shaji Kumar, Timothy J Kaufmann, Susan Geyer, Priya U Kumthekar, Jian Campian, Caterina Giannini, Jan C Buckner, Patrick Y Wen, Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance), Neuro-Oncology Advances, Volume 4, Issue 1, January-December 2022, vdac041, https://doi.org/10.1093/noajnl/vdac041. © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

Recommended Citation

Galanis, Evanthia; Campian, Jian; and et al., "Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)." Neuro-Oncology Advances. 4, 1. vdac041 (2022).
https://digitalcommons.wustl.edu/oa_4/741

Additional Links

Supplemental material is available for this article at publisher site.